Epitopoietic Research Corporation   Report issue

For profit Phase 2
Founded: Gembloux Isnes Belgium (2008)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2014
NCT01903330
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Epitopoietic Research Corporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 2)

Gliosarcoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 7